Impel NeuroPharma

49 articles with Impel NeuroPharma

• Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference

  6/16/2021

  Impel NeuroPharma today announced that the Company will present a corporate overview at the Raymond James Human Health Innovations Conference on Wednesday, June 23, 2021 at 3:20 p.m. ET.

• Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update

  6/7/2021

  Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD® technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2021 and produced a recent business update.

• 

  Clinical Catch-Up: June 1-6

  6/7/2021

  With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news.

• Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society

  6/2/2021

  Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response

• Impel NeuroPharma Launches Reroute Migraine Relief

  5/18/2021

  Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut.

• Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering

  4/22/2021

  Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its initial public offering of 5,333,334 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Impel.

• Impel NeuroPharma Partners With Veeva Systems to Build Integrated, Digital-First Commercial Foundation

  2/10/2021

  Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its pipeline of innovative medicines for central nervous system (CNS) diseases with high unmet needs.

• Impel NeuroPharma Announces U.S. Food & Drug Administration Acceptance Of New Drug Application For INP104 For The Acute Treatment Of Migraine

  1/20/2021

   Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults. INP104 is dihydroergotamine mesylate

• Impel Neuropharma Announces FDA Submission Of New Drug Application For INP104 For The Acute Treatment Of Migraine

  11/9/2020

  Dihydroergotamine mesylate (DHE) is Administered via Impel's Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper Nasal Space as a Potential Treatment Pathway

• Impel NeuroPharma Presents Data From Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine At 2020 Migraine Trust Virtual Symposium

  10/8/2020

  66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel's Proprietary Precision Olfactory Delivery (POD®) Technology with DHE May Offer Convenience, Clinical Benefit for Acute Migraine Patients

• 

  Clinical Catch-Up: June 29-July 3

  7/6/2020

  Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.

• Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105 for the Treatment of Acute Agitation in The Journal of Clinical Psychiatry

  6/30/2020

  Study Shows INP105 Achieves Rapid Absorption Which May Provide An Effective, Convenient, & Noninvasive Future Alternative for Treating Acute Agitation In the Home, Community, or Hospital Setting

• Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting

  6/15/2020

  Four Scientific Poster Presentations Support the Potential of INP104 to Fulfill Key Unmet Needs and If Approved, Become a Transformative New Therapeutic Option for Acute Migraine Additional Data from STOP 301, the Company's Pivotal Phase 3 Study of INP104 for Acute Migraine, Found Majority of Patients Reported INP104 Easy to Use and Preferred Over Current Acute Therapy Impel NeuroPharma Plans to Submit a New Drug Application (NDA) in the Second Half of 2020

• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

• Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine

  6/10/2020

  Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes At Weeks 21-24, Over 98% and 95% of Patients Who Experienced Pain Freedom at Two Hours Self-Reported No Recurrence of Migraine Symptoms or Use of Rescue Medications During the 24 and 48-Hour Periods, Respectively, After Using INP104 74%

• Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams' Role Expanded To Chairman And CEO

  5/5/2020

  Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of Adrian Adams , who served as Chairman of the Board of Directors since

• 

  Migraine Market: Biopharma Companies Working Toward Treatments

  2/25/2020

  BioSpace takes a look at some of the investigational products that could, one day, provide relief for migraine sufferers.

• Impel NeuroPharma Announces Appointment of Sheena K. Aurora, MD, As Vice President of Medical Affairs - Migraine Franchise

  1/16/2020

  Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Sheena K. Aurora, MD, as Vice President of Medical Affairs – Migraine Franchise.

• Impel NeuroPharma Announces Appointment Of Adrian Adams As Chairman Of The Board Of Directors

  1/9/2020

  Impel NeuroPharma announced the appointment of Adrian Adams as Chairman of the Board, effective January 8, 2020.

• Impel NeuroPharma Announces Appointment Of Diane Wilfong To Board Of Directors

  10/17/2019

  Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced that Diane Wilfong has been appointed to the Company's board of directors.